Haemonetics surges as CSL plans to move all US plasma centers to its devices
HAE•Haemonetics shares surged nearly 16% after the company said CSL Plasma expects to move all its U.S. centers to Haemonetics’ NexSys devices and kits by the end of 2027. BTIG estimates the business could add about 60 cents a year to adjusted EPS, though actual revenue and margins are not yet known.
1. CSL plans device switch
CSL Plasma expects to move all its U.S. plasma centers to Haemonetics’ NexSys devices and kits by the end of 2027. The move would win back business Haemonetics began losing in 2021, when CSL said it would not renew its U.S. supply deal.
2. Earnings estimate and rating
BTIG estimates the business could add about 60 cents a year to adjusted EPS, based on roughly $155 million Haemonetics earned from CSL’s U.S. business in fiscal 2024. The brokerage said actual revenue and margins are not yet known, kept its buy rating and raised its price target to $130 from $110. It said the deal eases concerns about market-share loss and lifts its sales-growth outlook.
